Collaboration yields E. coli discovery
The collaboration between the UK?s Health Protection Agency (HPA) and Thermo Fisher Scientific has led to a significant development in mapping the proteome of the organism responsible for the recent E. coli outbreak in Europe.
The collaboration between the UK’s Health Protection Agency (HPA) and Thermo Fisher Scientific has led to a significant development in mapping the proteome of the organism responsible for the recent E. coli outbreak in Europe. HPA researchers, using LTQ Orbitrap mass spectrometry technology, have identified the protein toxins expressed by the deadly strain that resulted in 37 deaths and made nearly 3400 people ill.
“The significance of this study is that scientists were able to develop techniques to study microorganisms and determine how the genetic code is being translated into the protein building blocks that determine traits such as toxicity,” said Dr Ian Jardine, vice president, global research and development, Thermo Fisher Scientific. “Our leading Orbitrap mass spectrometry system is providing researchers with the ability to understand what makes this E. coli strain so devastating, and may lead to an improved understanding of how to treat patients.”
Set up in 2003, the agency protects the public from the threats of infectious diseases and environmental hazards. The collaboration with Thermo Fisher studies the use of mass spectrometry to better understand the role of microorganisms in causing illness and disease in humans.
For more information on the technology, visit www.thermofisher.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
